A simplified method for treating Graves' disease with radioactive 131I

Area of Science:

• Endocrinology
• Nuclear Medicine

Background:

• Graves' disease is an autoimmune disorder causing hyperthyroidism.
• Radioactive iodine (131I) therapy is a common treatment for Graves' disease.
• Accurate diagnosis and effective dosing are crucial for successful treatment.

Purpose of the Study:

• To evaluate the efficacy and outcomes of 131I therapy for Graves' disease.
• To assess the reliability of short-term 123I uptake measurements for diagnosing hyperthyroidism.
• To propose a convenient and cost-effective treatment protocol for Graves' disease.

Main Methods:

• Retrospective review of 53 patients treated with 131I for Graves' disease.
• Prospective study of 21 patients to compare 4-hour and 24-hour 123I uptake measurements.
• Literature review to support treatment recommendations.

Main Results:

• High cumulative incidence of hypothyroidism (80% at 12 months) post-131I therapy.
• Rapid cure of hyperthyroidism with a low retreatment rate (7.5%).
• 4-hour 123I uptake measurement reliably predicted hyperthyroidism and 24-hour uptake.

Conclusions:

• 131I therapy is effective for Graves' disease, though hypothyroidism is a common sequela.
• A 4-hour 123I uptake test is a reliable diagnostic tool.
• A simplified treatment protocol using a 4 or 24-hour 123I uptake study followed by fixed-dose 131I is proposed.